Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to -$139748.0.

  • Immucell's Income towards Parent Company rose 8008.41% to -$139748.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 16097.25%. This contributed to the annual value of -$2.2 million for FY2024, which is 6265.32% up from last year.
  • Latest data reveals that Immucell reported Income towards Parent Company of -$139748.0 as of Q3 2025, which was up 8008.41% from $501880.0 recorded in Q2 2025.
  • Immucell's 5-year Income towards Parent Company high stood at $1.4 million for Q1 2025, and its period low was -$2.3 million during Q1 2023.
  • Moreover, its 5-year median value for Income towards Parent Company was -$441303.0 (2021), whereas its average is -$457589.9.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first crashed by 234979.9% in 2022, then surged by 43046.1% in 2025.
  • Immucell's Income towards Parent Company (Quarter) stood at $74134.0 in 2021, then tumbled by 2349.8% to -$1.7 million in 2022, then soared by 31.66% to -$1.1 million in 2023, then surged by 145.14% to $514555.0 in 2024, then crashed by 127.16% to -$139748.0 in 2025.
  • Its Income towards Parent Company stands at -$139748.0 for Q3 2025, versus $501880.0 for Q2 2025 and $1.4 million for Q1 2025.